Lilly, Resilience to invest $750 million in US drug manufacturing expansion

Reuters

Thu, July 30, 2026 astatine 7:58 AM CDT 1 min read

July 30 (Reuters) - Drugmaker Eli Lilly and privately held declaration shaper Resilience volition put $750 cardinal ‌to grow pharmaceutical manufacturing capableness successful the ‌U.S. and fortify the home medicine proviso chain, Resilience said connected ​Thursday.

Global drugmakers person been ramping up U.S. manufacturing since past twelvemonth and stockpiling inventory arsenic President Donald Trump's medication moves to enforce 100% tariffs connected branded ‌drugs unless companies ⁠cut prices oregon marque medicines domestically.

• Resilience said the concern volition summation the accumulation ⁠of captious medicines and make 400 caller high-skilled jobs successful the Cincinnati, Ohio region.

• The company's manufacturing ​operations successful ​the portion volition present ​include Lilly's KwikPen injectable ‌device for treating diabetes and obesity, it added.

• The multi-year manufacturing concern betwixt Lilly and Resilience, which began successful 2023, has already produced much than 150 cardinal doses of medicines for U.S. patients successful ‌vial and pre-filled syringe formats, ​according to Resilience.

• Lilly's manufacturing ​head Edgardo Hernandez ​said the concern reflects the drugmaker's ‌efforts to conscionable rising request ​for its medicines.

• ​Lilly's U.S. superior enlargement commitments since 2020 full much than $55 cardinal and it plans to ​break crushed connected ‌several of its precocious announced U.S. manufacturing ​sites this year.

(Reporting by Christy Santhosh successful Bengaluru; ​Editing by Jonathan Ananda)